Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update • First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '23 and 59% vs. Q4 '23 • Continued gross-to-net (GTN) improvement with blended GTN across products now in the low 60 percent range • Sustained growth in demand for cream and remarkable uptake of foam launched in January • July 7 ...

Core Insights - ZORYVE foam, a topical treatment for seborrheic dermatitis, has received strong endorsement from an expert dermatologist panel, indicating its suitability for diverse skin and hair types [1][3] - The formulation of ZORYVE foam is designed to be gentle and free from harmful ingredients, making it a versatile option for patients with various hair care practices [2][3] - ZORYVE foam is the first drug with a new mechanism of action approved for seborrheic dermatitis in over two decades, targeting the underlying inflammatory processes [5] Company Overview - Arcutis Biotherapeutics, Inc. is focused on developing innovative treatments for immune-mediated dermatological diseases, with a growing portfolio that includes FDA-approved products [8] - The company aims to address persistent patient challenges in dermatology through its unique development platform and expertise [8] Product Details - ZORYVE foam (roflumilast) is indicated for the treatment of seborrheic dermatitis in patients aged 9 years and older [6] - The foam formulation is a once-daily, steroid-free treatment that effectively delivers therapeutic agents to affected areas, including the scalp [1][5] - The formulation includes Crodafos CES, a gentle emulsifier that enhances compatibility with various skin and hair types [2][3]

Group 1 - Arcutis Biotherapeutics, Inc. will report its first quarter 2024 financial results and provide a business update on May 14, 2024, after U.S. financial markets close [1] - A conference call and webcast will be held on the same day at 4:30 p.m. ET, with a live webcast available on the company's website [1] - An archived replay of the webcast will be accessible on the Arcutis investor website following the conference call [1] Group 2 - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases [2] - The company has two FDA-approved products and a growing portfolio that addresses persistent patient challenges in dermatology [2] - Arcutis' development platform includes a robust pipeline with multiple clinical programs targeting inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [2]

Core Viewpoint - The stock price of Arcutis Biotherapeutics, Inc. (ARQT) has been on a bearish trend, losing 6.5% over the past two weeks, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1]. Technical Analysis - The hammer chart pattern indicates a potential bottom formation, suggesting that selling pressure may be subsiding [1][3]. - A hammer pattern typically forms during a downtrend when the stock opens lower, makes a new low, but then closes near or above the opening price, indicating a shift in control from bears to bulls [2][3]. Fundamental Analysis - There has been a significant upward trend in earnings estimate revisions for ARQT, with the consensus EPS estimate increasing by 6% over the last 30 days, indicating strong agreement among analysts about improved earnings potential [4]. - The Zacks Rank for ARQT is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperform the market [5].

Arcutis Biotherapeutics, Inc. (ARQT) closed the last trading session at $10.66, gaining 14.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $16.50 indicates a 54.8% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $6.44. While the lowest estimate of $8 indicates a 25% decline from the current price level, the most optimistic a ...

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children treated with roflumilast cream 0.05% achieved a 75% improvement in Eczema Area and Severity Index (EASI-75), a key secondary endpointNew data highlight rapid and significant reduction in itch as early as 24 hours following first application of roflumilast cream 0.05% based on daily Worst Itch Numeric Scale (WI-NRS ...

Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signatureSuggests skin barrier disruption in seborrheic dermatitis is distinct with its own disease-specific pattern SAN DIEGO, Calif., March 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, highlights new research that, for the first time, reveals the gene expression pro ...

Company Overview - Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on immuno-dermatology, addressing the needs of individuals with immune-mediated dermatological diseases [5] - The company has a growing portfolio that includes two FDA-approved products and a robust pipeline targeting various inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [5] Recent Offering - Arcutis announced the closing of its underwritten public offering of 18,157,895 shares of common stock at a price of $9.50 per share, resulting in total gross proceeds of approximately $172.5 million before deductions [1] - The offering included 2,368,421 shares issued upon the exercise of the underwriters' option to purchase additional shares [1] - Morgan Stanley, TD Cowen, and Guggenheim Securities acted as joint lead bookrunning managers for the offering, with Mizuho and Needham & Company serving as co-lead managers [2] Regulatory Compliance - The shares were offered pursuant to an effective shelf registration statement on Form S-3 filed with the SEC on January 31, 2024, with a final prospectus supplement available on the SEC's website [3]

Arcutis Biotherapeutics, Inc. (ARQT) closed the last trading session at $10.28, gaining 54.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $16.33 indicates a 58.9% upside potential.The average comprises six short-term price targets ranging from a low of $6 to a high of $38, with a standard deviation of $12.09. While the lowest estimate indicates a decline of 41.6% from the curre ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Arcutis Biotherapeutics, Inc. (ARQT) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Arcutis Biotherapeutics, Inc. is a member of our Medical group, which includes 1067 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector ...